USPTO serial 98160589
Reviewed by CopyMark Law Group
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
San Francisco, CA
San Francisco, CA
San Francisco, CA
Valrico, FL
Valrico, FL
Valrico, FL
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Andrew D. Bochner
Andrew D. Bochner BOCHNER PLLC1040 AVENUE OF THE AMERICAS15TH FLOORNEW YORK, NY 10018| Class | Description | Status | First use |
|---|---|---|---|
| 035 | Promoting the interests of cancer patients by means of public advocacy, specifically access and availability of generic drugs for cancer treatment; Promoting public awareness of supply chain issues of generic cancer treatment drugs by means of public advocacy; Pharmaceutical cost management services and drug utilization review services, namely, generic drugs for cancer treatment; Providing advertising, marketing and promotional services for the pharmaceutical and medical industry, namely, the manufacture and distribution of generic cancer treatment drugs; Promoting public interest and awareness of availability and accessibility of generic drugs for cancer treatment; Consulting in the field of distributorship services for pharmaceuticals, namely, generic drugs for cancer treatment | ACTIVE | — |
| 040 | Consulting services in the field of pharmaceutical manufacturing, namely, generic drugs for cancer treatment | ACTIVE | — |
| 044 | Pharmaceutical advice, namely, to facilitate and subsidize access to and availability of generic drugs for cancer treatment; Providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals, namely, generic drugs for cancer treatment | ACTIVE | — |
| 045 | Providing patient advocate services in the field of cancer treatment, namely, increasing access to and availability of generic drugs therefor; Providing patient advocate and case management services, namely, coordinating the procurement and administration of medication, specifically for generic drugs for cancer treatment; Providing information about legal eligibility requirements for government medical and pharmaceutical programs, namely, for access to and availability of generic drugs for cancer treatment | ACTIVE | — |
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 3, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Dec 3, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 10, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 10, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 21, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 6, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 6, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 6, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Aug 6, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 6, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Aug 5, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 5, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 5, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 4, 2024 | AAUA | NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED | — |
| May 3, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 3, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 3, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 3, 2024 | IUAA | USE AMENDMENT ACCEPTED | — |
| Apr 30, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 7, 2024 | AUPC | AMENDMENT TO USE PROCESSING COMPLETE | — |
| Feb 7, 2024 | IUAF | USE AMENDMENT FILED | — |
| Feb 6, 2024 | EAAU | TEAS AMENDMENT OF USE RECEIVED | — |
| Sep 27, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 5, 2023 | NWAP | NEW APPLICATION ENTERED | — |